Everest Medicines is a late clinical-stage biopharmaceutical company focused on licensing, developing and commercializing globally innovative therapies with the mission of addressing critical unmet medical needs in Greater China and other emerging Asia Pacific markets.

Our world-class clinical and regulatory teams, insight-driven business development engine and integrated commercial platform position us to accelerate the availability of innovative new medicines to patients.

Since our inception in 2017, we have assembled a portfolio of eight promising clinical-stage drug candidates for oncology, immunology, cardio-renal disease and infectious disease. We have targeted these four therapeutic areas based on the severity of the unmet medical needs, the size of the at risk patient population, and the emergence of innovative products globally.